CAMBRIDGE, Massachusetts, August 28, 2026, 09:47 (EDT) – Moderna shares declined by 3.4% as the company launched a $2.6 billion convertible bond offering, putting its recent rally following positive news on its cancer vaccine under scrutiny.
- Shares of Moderna dropped 3.4% to $137.86 as of 09:46 EDT.
- The company set the price for $2.6 billion in zero-coupon notes scheduled to mature in 2032.
- The initial conversion amounts to approximately 12.3 million shares prior to the capped-call hedge.
Moderna Inc. (NASDAQ: MRNA) shares declined 3.4% on Friday following the vaccine company’s pricing of an expanded $2.6 billion convertible-note sale. The stock was changing hands at $137.86 as of 09:46 EDT, with 5.5 million shares traded.
The drop wiped out roughly $2.0 billion in market value. Investors are balancing inexpensive capital with the risk of future dilution following a major cancer-vaccine surge.
The notes do not pay periodic interest and are scheduled to mature in March 2032. Moderna anticipates net proceeds of $2.563 billion, prior to any purchaser exercising their option financing terms.
| Financing measure | Reported term | Investor reading |
|---|---|---|
| Principal | $2.6 billion | Raised from $2.0 billion |
| Coupon | 0.00% | No periodic cash interest |
| Initial conversion price | $210.58 | 47.5% above Thursday’s closing price of $142.77 |
| Initial underlying shares | About 12.3 million | Roughly 3.1% of shares at end of June |
| Capped-call ceiling | $392.6175 | Hedge covers up to 175% above Thursday’s close |
| Expected net proceeds | $2.563 billion | Represents about 37% of liquidity at end of June |
Every $1,000 bond can be exchanged for 4.7487 Moderna shares at the outset. This totals roughly 12.3 million shares, equivalent to 3.1% of the 398 million shares Moderna reported in June.
The capped-call deals cost approximately $285 million. Their purpose is to counter dilution or additional cash payments up to a cap of $392.6175.
The impact on the balance sheet is significant. As of June 30, Moderna reported $6.9 billion in cash and investments, and subsequently made a $950 million litigation settlement payment in July second-quarter filing.
The company reported second-quarter revenue of $145 million, with a loss of $0.8 billion, and forecasts year-end cash between $4.7 billion and $5.2 billion.
The timing reflects Moderna’s cash situation. The new financing boosts operational flexibility as the company works on its oncology pipeline and weighs options for debt repayment.
The capital raising came after U.S. authorization of updated Spikevax and mNEXSPIKE vaccines for the XFG variant. The approvals apply to older adults as well as younger patients at high risk Reuters.
COVID products continue to be a key source of revenue in the short term. However, U.S. vaccine sales declined in the second quarter, making the autumn rollout more critical.
Wall Street analysts are split following Moderna’s latest rally. The prevailing recommendation is Hold, with an average price target of $106.63, which is under Friday’s closing price analyst snapshot.
Risks: An increase in share price could lead to conversion even with the hedge in place. Demand for vaccines may fall short of expectations, and oncology investment could deplete the additional capital ahead of revenue generated by approvals.
Related articles: NASDAQ:MRNA
